Strong IP Protections Critical to Maintaining Robust Innovation Cycle
Update: 2025-06-02
Description
Henry Hadad, Senior Vice President and Deputy General Counsel at Bristol-Myers Squibb, discusses how intellectual property (IP) protection is very much a natural right that encourages - not discourages - innovation, the incremental erosion of IP protections over the last 20 years, how the AI revolution is going to have a significant impact on the biopharmaceutical industry, and the need to restore and maintain the right balance between access and innovation to avoid slowing down biopharma’s robust innovation cycle.
Comments
In Channel






















